Pancreatic Cancer Therapy Shows Promise
In an interesting advance for pancreatic cancer patients, a new treatment has shown promising results when combined with various types of chemotherapy before surgery. A pilot study presented at the American Association for Cancer Research’s (AACR) annual meeting unveiled encouraging findings that suggest improved outcomes for pancreatic cancer patients.
Key Findings and Implications
The study, which observed 28 trial participants, revealed that 24 patients who received the new Nivolumab drug and chemotherapy combination before surgery experienced no grade 2 post-operative fistulas. Furthermore, after two years, the combination therapy demonstrated a median progression-free survival rate of 34.8 months, with a median overall survival rate recorded at 35.1 months. Importantly, no unexpected safety signals were reported, and the addition of Opdivo did not escalate the rates of grade three adverse events.
Michelle Stewart, CEO of PanKind Australia, commented on the significance of these findings, stating, "While this study is very small and still at an early stage, the promising results of Nivolumab in neoadjuvant pancreatic cancer treatment may offer hope for patients and their families. This innovative approach needs further study before it can be used widely but if successful has the potential to improve outcomes and bring us closer to finding effective treatments for this challenging disease."
The study marks a significant milestone as it represents the first trial reported of a PD1 inhibitor in neoadjuvant pancreatic cancer. Currently, a Phase II trial is underway to further investigate the efficacy and safety of this treatment.
These findings underscore the importance of ongoing research and collaboration in the fight against pancreatic cancer.
The Road Ahead in Pancreatic Cancer Treatment
As we continue to advance in our understanding and treatment of pancreatic cancer, studies like this offer renewed hope and optimism for the future. With dedication, innovation, and perseverance, we strive towards a world where pancreatic cancer is no longer a life-threatening diagnosis.
About PanKind
PanKind, The Australian Pancreatic Cancer Foundation, is exclusively dedicated to pancreatic cancer, with a mission to dramatically increase survival rates and quality of life for those impacted by the disease.
MORE ON PANCREATIC CANCER RESEARCH
- PBAC reviews new treatment
- Impact in Research 2023
- Improvements in Surgical Practice: ScanPatient Trial
Sign up to our newsletter and follow us on facebook, instagram, linkedin and twitter to keep up-to-date with the latest news, upcoming events, personal stories and exciting breakthroughs.